**ORIGINAL ARTICLE**

Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study

Petra Czarniak | Fariba Ahmadizar | Jeff Hughes | Richard Parsons | Maryam Kavousi | Mohammad Ikram | Bruno H. Stricker

1Curtin Medical School, Curtin University, Perth, Western Australia, Australia
2Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands

**Aim:** To investigate the association between proton pump inhibitors (PPIs) and risk of incident diabetes in a follow-up study and to investigate its potential mechanisms.

**Methods:** A total of 9531 individuals without type 2 diabetes (T2DM) at baseline were included from the Rotterdam Study, a prospective population-based cohort of 14,926 individuals aged 45 years or older. During the study period (1 April 1997 to 1 January 2012) all incident cases of T2DM were enrolled. We used multivariable linear regression analysis to investigate the associations of baseline PPI use and various serum biomarkers (eg, serum magnesium, insulin-like growth factor 1) which might modify the association. Thereafter, we excluded prevalent PPI users and performed a Cox proportional hazard regression analysis to explore the time-varying effect of incident PPI use on T2DM during follow-up.

**Results:** Baseline use of a PPI was associated with increased serum levels of fasting insulin (0.091 pmoL/L, 95% confidence interval [CI] 0.049, 0.133), homeostasis model assessment-insulin resistance (0.100, 95% CI 0.056, 0.145) and C-reactive protein (0.29 mg/L, 95% CI 0.198, 0.384), but decreased levels of magnesium (−0.009 mmol/L, 95% CI −0.014, −0.004) and IGF-1 (−0.805 nmol/L, 95% CI −1.015, −0.595). After adjustment for risk factors such as physical activity and body mass index/waist-to-hip ratio, current use of PPI was associated with an increased risk of incident T2DM (hazard ratio [HR] 1.69, 95% CI 1.36–2.10). The effect was dose-dependent with the highest risk (HR 1.88, 95% CI 1.29–2.75) in those on more than one defined daily dose.

**Conclusion:** New users of PPIs during follow-up had a significantly higher dose-dependent risk of incident diabetes. We suggest vigilance regarding their potential adverse effect on glucose homeostasis.

**Keywords**
C-reactive protein, hypomagnesemia, insulin resistance, insulin-like growth factor, proton pump inhibitors, serum insulin, type 2 diabetes

P. Czarniak and F. Ahmadizar contributed equally to the manuscript
The Principal Investigators for this paper were P. Czarniak and F. Ahmadizar.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

2718 | wileyonlinelibrary.com/journal/bcp

Br J Clin Pharmacol. 2022;88:2718–2726.
INTRODUCTION

The global prevalence of type 2 diabetes (T2DM) in 2015 of approximately 5.5% is predicted to rise to almost 11% by 2045. The worldwide focus on T2DM prevention has highlighted the need to understand the pathophysiological changes leading to diabetes. However, the aetiology of T2DM is complex and involves multiple genetic and nongenetic factors, including drugs with an effect on glucose levels.

Proton pump inhibitors (PPIs) are commonly used medications in the treatment of acid-related disorders including peptic ulcer disease, gastro-oesophageal reflux disease (GORD), and Zollinger-Ellison syndrome. These medications suppress H⁺/K-ATPase present in parietal cells of the gastric mucosa and inhibit gastric acid secretion until replacement pumps can be synthesized. Human studies have shown that insulin secretion is increased in moderate hypergastrinemia. In line with this, a retrospective cohort study within a healthcare database showed a significantly reduced risk of developing T2DM of 20% in patients with upper gastrointestinal disease using PPIs. However, more recent studies suggested that PPIs may increase the risk of T2DM. A randomized controlled trial with a median follow-up of 3 years showed a 15% nonsignificantly increased risk of T2DM associated with pantoprazole, and a recently published analysis in three prospective cohort studies with interview data showed a significant risk increase of T2DM of 24% in regular PPI users.

What this study adds

- Incident use of PPI was associated with a significantly increased risk of incident diabetes.
- The effect was dependent on dosage and duration of PPI use.
- Whilst the mechanism of glycaemic dysregulation associated with PPI use requires further investigation, low magnesium and glucagon-like peptide-1 are potential contributors.

METHODS

2.1 Study setting

This study is embedded within the framework of the Rotterdam Study (RS), a prospective population-based study in three cohorts of predominantly Caucasian background with altogether 14,926 individuals ≥45 years of age living in the well-defined Ommoord district of Rotterdam, the Netherlands. The participants were all extensively examined at study entry, ie, in baseline and subsequent follow-up visits that take place every 3-6 years. They were interviewed at home and then underwent an extensive set of examinations, eg, echocardiogram, echocardiography, computed tomography-scanning and magnetic resonance imaging with an emphasis on imaging (of heart, blood vessels, eyes, skeleton and later brain) and on collecting biospecimens that enabled further in-depth molecular and genetic analyses. The participants in the Rotterdam Study are followed for a variety of diseases that are frequent in the elderly, which include coronary heart disease, heart failure and stroke, and dementia, but also several other chronic diseases such as diabetes and cancer. All physician visits, hospitalizations and pharmacy data are captured.

The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus Medical Centre (Erasmus MC) (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalog number NTR6831. Participants provided written informed consent to participate in the study. The complete design and rationale behind the Rotterdam Study are described in a separate publication. The study was also approved by the Curtin University Human Research Ethics Committee (Approval number: HRE2017-0095).

In this study, the following examination rounds were considered as a baseline for our analysis: (1) the third examination of the first cohort (held between 1997 and 1999, which followed a total of 7983
participants aged ≥55 years, RS-I), (2) the first examination of the second cohort (held between 2000 and 2001, which followed a total of 3011 participants aged ≥55 years, RS-II) and (3) the first examination of the third cohort (held between 2006 and 2008, which followed a total of 3932 participants aged ≥45 years, RS-III). From 10,696 participants eligible for this study, we excluded participants with prevalent T2DM at baseline (n = 1165). For the association between PPIs and incident T2DM, we also excluded participants with the prevalent use of PPIs at baseline (n = 656).

2.2 | Study designs

We performed two analyses. First, we performed a cross-sectional analysis to study the association between prevalent PPI use at baseline and biomarkers as defined below. Second, we completed a longitudinal study in individuals without a history of PPI use at baseline to examine the association of incident PPI use with incident T2DM. In this follow-up analysis, PPI use was analyzed as a time-varying exposure. In this design, PPI exposure preceding the first incident case of T2DM was compared to PPI exposure preceding the same day of follow-up in each participant without T2DM in the remainder of the cohort. This meant that each participant, cases as well as noncases, had the same day of follow-up as an index date (date of incident T2DM) which served as a reference to assess exposure on that date. The details of this method have been published previously.12

2.3 | Measurement of exposure

Drug exposure was monitored continuously from 1 January 1991 through linkage with pharmacy records of all pharmacies in the study district. Dispensing data on PPI use, including dispensing date, Anatomical Therapeutic Chemical (ATC) code, prescribed daily dose and the amount prescribed was obtained from all pharmacies in the study district. The prescription duration was calculated as the number of dispensed tablets, divided by the prescribed daily number and a participant was considered as exposed to PPI if the index date fell within the prescription duration period. For all individuals, their PPI use at each index date was classified into one of the following categories: “current use”, “past use”, or “never use”. A person was classified as a current user if their follow-up date for that stratum occurred within a prescription episode of PPIs. If a participant had previously used PPIs during follow-up but was not a current user at the index date, they were classified as a “past user”. They were classified as a “never user” if they had not taken a PPI during the study period at any time before the index date. The cumulative duration of PPI use during the study period was classified into four groups: no use, 1-90 days, 91-730 days.
and >730 days. The dose of PPI on the index date was classified as no use, low (<1 defined daily dose [DDD]), moderate (1 DDD) or high (>1 DDD) dose, as defined by the World Health Organization.\textsuperscript{13}

### 2.4 Measurement of outcomes

#### 2.4.1 Baseline biomarkers

All biochemical variables were assessed in serum samples taken after overnight fasting. Serum fasting glucose (mmol/L) concentration was measured using the glucose hexokinase method within 1 week after sampling and insulin concentration (pmol/L) by metric assay (Biosource Diagnostics, Camarillo, CA, USA). Serum fasting glucose (mmol/L) and serum fasting insulin (pmol/L) levels were measured at the Erasmus MC research center. To measure insulin resistance, we calculated the HOMA-IR index by the following formula: (fasting serum insulin (mU/L) \times fasting serum glucose (mmol/L))/22.5.\textsuperscript{14}

Serum magnesium (mmol/L) was measured by the Department of Clinical Chemistry of the Erasmus MC using a Roche/Hitachi Cobas c501 analyzer. Serum IGF-I (nmol/L) was measured with a commercially available noncompetitive two-site immunoradiometric assay.\textsuperscript{15}

CRP (mg/L) was measured by sensitive immunologic methods using an in-house enzyme immunoassay (n = 516 subjects; Dako, Glostrup, Denmark) or a nephelometric method (n = 160; Dade-Behring, Marburg, Germany), with high agreement of these two methods.\textsuperscript{16}

#### 2.4.2 Type 2 diabetes diagnosis

We identified incident T2DM by use of general practitioner records, hospital discharge letters, pharmacy dispensing data and serum fasting glucose measurements taken at the study centre visits. During follow-up, study participants visited the research center at 4-year intervals. During these visits, incident T2DM was defined according to WHO guidelines as a fasting serum glucose level of ≥7.0 mmol/L or a nonfasting serum glucose concentration of ≥11.1 mmol/L (when fasting serum samples were not available) or the use of blood glucose-lowering medications. Two physicians independently adjudicated all potential events of T2DM. In case of disagreement, a consensus was achieved by an endocrinologist.\textsuperscript{17} We included all cases of incident T2DM between 1 April 1997 and 1 January 2012.

#### 2.4.3 Covariables

At baseline, information was obtained on individuals’ characteristics, medical and medication history, health status and lifestyle factors. Baseline body mass index (BMI) was calculated by dividing body weight in kilograms by the square of height in metres. The waist-to-hip ratio (WHR) was calculated as waist circumference/hip circumference. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or antihypertensive medication use. Information on smoking habits and current alcohol consumption was obtained during a home interview. Physical activity levels were assessed using a validated adapted version of the Zutphen Physical Activity Questionnaire.\textsuperscript{18}

#### 2.4.4 Statistical analysis

We performed descriptive statistics including the mean (standard deviation, SD) or median (interquartile range, IQR) for continuous variables and numbers (percent) for categorical variables to summarize the profile of the participants at the time of their entry into the study. Where needed, skewed variables were log-transformed.

The cross-sectional associations between baseline PPI with biomarkers including glycemic traits, serum magnesium, serum IGF-1 and CRP were investigated using multivariable linear regression analyses. Because of skewness in the distributions of these biomarkers, their natural logarithms were used in the models. Results were reported as the adjusted mean differences associated with PPI use and their 95% confidence intervals (CI). All analyses were adjusted for age and sex (Model 1), and further adjusted for BMI, hypertension, current smoking, alcohol consumption, physical activity and education levels (Model 2).

In the longitudinal study in individuals without T2DM and without a history of PPI use at baseline, we used Cox proportional hazard regression analysis to explore the association of (i) PPI current use (yes/no), (ii) duration of PPI use (three categories) and (iii) dosage of PPI (three categories) with incident T2DM in which PPI use was analysed as a time-varying exposure. In this type of Cox regression, PPI exposure preceding the first incident case of T2DM was compared to PPI exposure preceding the same day of follow-up in each participant without T2DM in the remainder of the cohort. This meant that each participant, cases as well as noncases, had the same day of follow-up as an index date (date of incident T2DM) which served as a reference to assess exposure on that date. Consequently, noncases may serve as a reference for a case of T2DM on multiple time points during follow-up. Details of this method have been published previously.\textsuperscript{12} All analyses were adjusted for age, sex and PPI past use (except for the duration of use) (Model 1), and further adjusted for BMI, hypertension, current smoking, alcohol consumption, physical activity and education levels (Model 2). We also included interaction terms in Model 2 to study whether any significant associations were modified by sex, age, serum magnesium, IGF-1 or CRP.

In a series of sensitivity analyses in Model 2, the associations between PPI current use and incident T2DM were further adjusted for baseline measurements of (i) total cholesterol, high-density lipoprotein-cholesterol and lipid-lowering medications, (ii) WHR, (iii) statin use, (iv) serum magnesium, (v) serum IGF-I receptor stimulating activity and (vi) CRP. Furthermore, the analysis was performed after excluding prevalent prediabetes (serum fasting glucose 6.1-6.9 mmol/L). The longitudinal analyses were also repeated using different definitions of PPI current use in which we subtracted 1 year (cumulative PPIs) from the index date in T2DM cases (in noncases 1 year from the same date of follow-up) and the associations with PPI
use until that date were studied. We also studied whether there was an association between the use of histamine-2 (H2) receptor-blockers (used for similar indications as PPIs) and incident T2DM to exclude that an association might be confounded by the indication. Finally, apart from excluding prevalent PPI users at baseline (to exclude immortal time bias), we excluded every study participant with a history of PPI use before baseline, retaining 7383 for our analyses on PPI use (current, past, duration and dose) and incident T2DM.

3 | RESULTS

3.1 | Baseline characteristics

We included 9531 participants free of T2DM at baseline (Table 1). The majority of participants were female (5555, 58.3%) and the mean age of the population was 64.8 years. The mean BMI was 27.0 kg/m².

**Table 1** Demographic and baseline characteristics of the study participants

| Characteristic | Total population (n = 9531) |
|---------------|-----------------------------|
| Age, years    | 64.8 (10.0)                 |
| Sex, female, n (%) | 5555 (58.3)        |
| Baseline glucose, mmol/L, median (IQR) | 5.4 (5.0-5.8) |
| Baseline insulin, pmol/L, median (IQR) | 67.0 (46.0-97.0) |
| HOMA-IR index, median (IQR) | 2.3 (1.5-3.4) |
| Alcohol intake, g/d, median (IQR) | 3.7 (0.30-15.7) |
| BMI, kg/m², mean (SD) | 27.0 (4.1) |
| Obese (BMI ≥ 30), n (%) | 1707 (18%) |
| Total cholesterol, mmol/L mean (SD) | 5.8 (1.1) |
| Triglycerides, mmol/L mean (SD) | 1.5 (2.4) |
| HDL-cholesterol, mmol/L, median (IQR) | 1.4 (1.1-1.7) |
| Lipid-lowering medications, n (%) | 1714 (18.0) |
| Physical activity, median, MET hour (IQR) | 62.2 (30.8-97.0) |
| Hypertension, n (%) | 5601 (58.8) |
| Blood-pressure lowering medications, n (%) | 3011 (31.6) |
| Magnesium, mmol/L mean (SD) | 0.85 (0.06) |
| IGF-1, nmol/L, median (IQR) | 2.3 (1.0-13.9) |
| CRP, mg/L, median (IQR) | 1.5 (0.6-3.34) |
| PPI use at baseline date, n (%) | 656 (6.9) |

Note: Hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or antihypertensive medication use. Abbreviations: IQR, interquartile range; HOMA-IR, homeostasis model assessment-insulin resistance; SD, standard deviation; BMI, body mass index; HDL, high-density lipoprotein; PPI, proton pump inhibitor; IGF-1, insulin-like growth factor 1.

As shown in Table 2, in Model 2 of adjustment, baseline use of a PPI was associated with significantly increased fasting insulin levels (mean difference 0.091 [0.049, 0.133]), HOMA-IR (mean difference 0.100 [0.056, 0.145]) and CRP levels (mean difference 0.29 [0.198, 0.384]). There were also statistically significant associations between the use of PPIs and decreased levels of magnesium (mean difference −0.009 [−0.014, −0.004]) and serum IGF-1 receptor stimulating activity levels (mean difference −0.805 [−1.015, −0.595]).

3.2 | Association of PPI use with biomarkers

Out of 899 patients who developed T2DM, 29.2% were obese. Of these obese persons with T2DM during follow-up, 25.3% were exposed to PPI as against 23.7% in obese participants without T2DM. Our analyses showed that in Model 2 adjustment, current PPI use was associated with an increased risk of incident T2DM (HR 1.69, 95% CI 1.36-2.10). During follow-up, the proportion of current users of PPI on the index date of the total population was 4.8% for omeprazole (HR 1.76, 95% CI 1.39-2.23), 1.7% for pantoprazole (HR 1.98, 95% CI 1.38-2.82), 1.3% for lansoprazole (HR 1.22, 95% CI 0.70-2.11), 2.2% for rabeprazole (HR 1.32, 95% CI 0.92-1.91) and 1.1% for esomeprazole (HR 1.96, 95% CI 1.26-3.02). The associations were lower but remained statistically significant in PPI past users (1.24, 95% CI 1.05-1.45) (Table 3 and Figure 1). As for the cumulative duration of use, the highest risk of incident T2DM was associated with PPI use for a duration longer than 731 days (1.49, 95% CI 1.14-1.95, P value <0.01), which became even stronger after excluding participants with a history of PPI use before baseline (Table 4). There was also a dose-response trend in the association between PPI dose from low dose (1.61, 95% CI 1.05-2.46) to high dose (1.88, 95% CI 1.29-2.75). Sex (P value = 0.23), age (P value = 0.92), serum magnesium (P value = 0.45), IGF-1 (P value = 0.35) and CRP (P value = 0.72) did not modify the associations between PPI use and incident T2DM.

As shown in Table 4, in a series of sensitivity analyses adding more potential confounders to Model 2, adjustment attenuated the effect estimates but the association of current PPI use and incident T2DM remained statistically significant. When excluding prediabetic cases from the analysis, the association between current PPI use and incident T2DM was even stronger (1.82, 95% CI 1.41-2.34).
| TABLE 2 | Association of PPI use and incident type 2 diabetes (n = 8875) |
|---------|--------------------------------------------------|
|          | Model 1, hazard ratio (95% CI) | Model 2, hazard ratio (95% CI) |
| No PPI use | 1.00 (reference) | 1.00 (reference) |
| PPI past use | 1.29 (1.10-1.51) | 1.24 (1.05-1.45) |
| PPI current use | 1.79 (1.45-2.22) | 1.69 (1.36-2.10) |
| PPI duration |                      |                      |
| No use | 1.00 (reference) | 1.00 (reference) |
| <90 d | 1.40 (1.16-1.68) | 1.38 (1.14-1.67) |
| 91-730 d | 1.33 (1.05-1.69) | 1.20 (0.94-1.53) |
| >731 d | 1.59 (1.22-2.07) | 1.49 (1.14-1.95) |
| Dose categories** |                      |                      |
| No use | 1.00 (reference) | 1.00 (reference) |
| <1 DDD | 1.69 (1.11-2.58) | 1.61 (1.05-2.46) |
| =1 DDD | 1.77 (1.35-2.33) | 1.65 (1.25-2.17) |
| >1 DDD | 1.93 (1.32-2.82) | 1.88 (1.29-2.75) |

Note: Model 1 adjusted for age and sex, PPI past use (not for the duration of use) (for association between PPI past use and incident T2DM, the association was adjusted for current PPI use). Model 2 is model 1 additionally adjusted for BMI, hypertension, current smoking, alcohol consumption, physical activity and education levels. Hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or antihypertensive medication use. Abbreviations: CI, confidence interval; PPI, proton pump inhibitor; IGF-1, insulin-like growth factor 1. **P value for trend < .001.

P value for the interactions of:
PPI dose × sex = .23.
PPI dose × age = .92.
PPI dose × magnesium = .45.
PPI dose × IGF-1 = .35.
PPI dose × CRP-1 = .72.

| TABLE 3 | Association of PPI use and glycaemic traits, magnesium and IGF-1 at baseline |
|---------|--------------------------------------------------|
| Baseline PPI use | Model 1, mean difference, 95% CI | Model 2, mean difference, 95% CI |
| Serum glucose, mmol/L (n = 8841) | 0.053 [0.006, 0.10] | 0.014 [−0.032, 0.059] |
| Serum insulin, pmol/L (n = 8656) | 0.190 [0.143, 0.246] | 0.091 [0.049, 0.133] |
| HOMA-IR (n = 8603) | 0.207 [0.158, 0.257] | 0.100 [0.056, 0.145] |
| Magnesium, mmol/L (n = 8607) | −0.010 [−0.015, −0.005] | −0.009 [−0.014, −0.004] |
| IGF-1, nmol/L (n = 1220) | −0.83 [−1.04, −0.623] | −0.805 [−1.015, −0.595] |
| CRP, mg/L (8,548) | 0.39 [0.294, 0.488] | 0.29 [0.198, 0.384] |

Note: Model 1 adjusted for age and sex. Model 2 is Model 1 additionally adjusted for BMI, hypertension, current smoking, alcohol consumption, physical activity and education levels. Hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or antihypertensive medication use. To achieve a normal distribution, serum insulin, HOMA-IR, IGF-1 and CRP were log-transformed. To interpret the amount of change in the original metric of serum insulin, HOMA-IR, IGF-1 and CRP, we used the exponents of the beta coefficients. Abbreviations: PPI, proton pump inhibitor; SE, standard error; HOMA-IR, homeostasis model assessment-insulin resistance; IGF-1, insulin-like growth factor 1; CRP, C-reactive protein.

However, the associations of current PPI use and incident T2DM 1 year before the diagnosis of T2DM after subtracting a 1-year lag time did not remain statistically significant. We also studied the association between histamine-2 receptor blockers and incident T2DM, where the association was not significant (0.94, 95% CI 0.57-1.54). When we excluded individuals with a history of PPIs at baseline, all associations of incident PPI use and incident T2DM remained statistically significant and often stronger (Table 4).

4 | DISCUSSION

In this prospective population-based cohort study in middle-aged and elderly people without diabetes at baseline, incident use of PPI was associated with a significantly increased risk of incident diabetes during follow-up, after adjustment for known risk factors such as physical activity, BMI or WHR. The effect was dose-dependent in current users of PPI, duration-dependent and declined in past users. Interestingly, users of PPI at baseline (who were excluded from the follow-up...
analyses) had significantly higher serum fasting insulin levels, insulin resistance and CRP but lower serum levels of magnesium and IGF-1. Adjusting for these baseline biomarkers during follow-up in incident users did not impact the association of PPI use with incident T2DM. Although there were slight differences in risk estimates and significance between the individual PPIs omeprazole, pantoprazole, lansoprazole, rabeprazole and esomeprazole, these differences were not materially different and probably partly explained by different sample sizes.

These findings are in line with an earlier analysis in three cohorts in the United States but the risk in the current study is higher. One explanation might be that the use of PPI in these cohorts came from repeated 2-year interviews, which may have led to nondifferential misclassification of PPI use with an underestimate of the true risk. Although exposure during repeated interviews may serve as a proxy indicator of continuous use, drug dispensing is a more reliable data source.

Several potential underlying mechanisms may be involved in the contribution of PPIs to the development of T2DM, including PPI-induced hypomagnesemia, changes to the gut microbiome, IGF-1 or pregnane X receptor activation (Figure 1). First, an inverse relationship has been reported between dietary magnesium intake and risk of developing T2DM, which is in line with the results of our study where low baseline magnesium was associated with T2DM during follow-up (data not shown). Hypomagnesemia has been reported to be associated with increased insulin resistance and possibly reduced insulin secretion. In our study, PPI at baseline was associated with low serum magnesium, and also in a recent meta-analysis of observational studies researchers reported a significant association between PPI use and hypomagnesemia. In a study investigating the extent to which magnesium intake is related to systemic inflammation and metabolic syndrome, researchers reported that magnesium intake was inversely associated with plasma CRP concentrations. They also reported low magnesium intake was inversely associated with the prevalence of metabolic syndrome. CRP is a measure of systemic inflammation, which is thought to be a common mechanism underlying the development of metabolic-related disorders such as T2DM. Although in our study PPI-associated T2DM was independent of baseline serum magnesium, it is still possible that individuals starting with PPI during follow-up developed hypomagnesemia, and that PPI-lowered serum magnesium was an intermediate step in the causal pathway.

Second, in our study PPIs were associated with a lower IGF-1, a hormone with structural homology to insulin, which is produced primarily by the liver on stimulation by growth hormone. It has a positive impact on glucose homeostasis by improving insulin sensitivity by decreasing hepatic glucose production and increasing peripheral glucose uptake. Low IGF-1 levels have been found in obesity, metabolic syndrome and diabetes. In a recent cross-sectional study investigating the effects of PPIs on IGF-1 in 938 older people, PPI use was independently and negatively associated with IGF-1 levels. Both low and high IGF-1 levels are related to impaired glucose tolerance and a higher risk of T2DM.

A third mechanism might involve the gut microbiota. PPIs have been reported to influence the composition of the gut microbiota, producing small intestine bacterial overgrowth or dysbiosis. Gut microbiota breaks down indigestible carbohydrates to various metabolites, the most abundant of which are the short-chain fatty acids acetate, butyrate and propionate. They exert systemic anti-inflammatory effects by producing immunosuppressive cytokines and immunoglobulin A. They also promote the secretion of glucagon-like peptide-1 (GLP-1), an incretin hormone released by L-cells, which results in a reduction in appetite, delayed gastric emptying, glucose-dependent insulin secretion and inhibition of glucagon secretion. The release of enteroendocrine cell hormones such as GLP-1 may be influenced by the gut microbiota. Hence depending on the composition of the host microbiome, this may influence GLP-1 release and therefore glucose homeostasis and risk of developing T2DM.
A fourth mechanism might follow activation of pregnane X receptor (PXR), a ligand-activated nuclear receptor that has been reported to be associated with the regulation of hepatic glucose metabolism.\textsuperscript{37} PXR is activated by various chemicals known to induce CYP3A4 gene expression, including PPIs.\textsuperscript{38} Despite PXR activation suppressing gluconeogenesis, it has been reported to impair glucose tolerance, possibly by downregulation of the hepatic glucose transporter 2.\textsuperscript{37} Due to its detrimental role in the regulation of glucose metabolism, activation of PXR may contribute to the development of T2DM.\textsuperscript{37}

Alternatively, there might be a role for gastrin, which is supposed to improve glucose control. Gastrin may stimulate beta-cell proliferation and function.\textsuperscript{33,39} Indeed, users of PPI had significantly higher fasting insulin in our study. We postulate that long-term gastrin release may exhaust this mechanism and consequently increase the risk of T2DM.

There were several strengths associated with this study. The most important strengths were the availability of data on important biomarkers such as serum magnesium and IGF-1, PPI dose and duration of treatment, and the long follow-up in community-dwelling middle-aged and elderly people free of T2DM at baseline. As this was a population-based study that gathered data prospectively, there is a reduced likelihood of information and selection bias. Moreover, we studied people without a history of PPI use at baseline, which means that a “healthy user effect” or misclassification of a duration of exposure cannot explain our results. However, there is a potential limitation to consider as well, ie, risk of diagnostic bias if people who regularly consult their doctor for a prescription of PPI might more readily obtain a diagnosis of T2DM. This is unlikely, however, for three reasons. First, the case finding was mainly based on a prospective regular investigation of study participants at 4-year intervals irrespective of drug use and specialist-based diagnoses of T2DM in between. Second, a lag time of 1 year subtracted from diagnosis of T2DM still showed an increased risk in PPI users, albeit lower and no longer significant for current use but still for duration of use. Third, there was no association whatsoever with the use of H2-blockers, which are used for the same indications as PPI. Unfortunately, we did not have repeated data on magnesium level, IGF-1 and gut microbiota, which could have yielded important information on the mechanism.

In conclusion, PPI use is associated with the onset of T2DM, and its risk increases with daily dose and duration of use. This risk increase seems higher than previously reported. Given the very large-scale use of PPI, including the over-the-counter availability in many countries and the increasing prevalence of diabetes, the large-scale and free availability of PPI might have to be reconsidered. Also, our findings underline the need to be vigilant regarding metabolic adverse effects. In high-risk individuals (eg, obese, prediabetic) using PPI therapy regularly or for prolonged periods, glucose monitoring may be justified.

ACKNOWLEDGEMENTS

The authors thank all the participants in the Rotterdam Study. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sector.

COMPETING INTERESTS

No potential conflicts of interest relevant to this article were reported.

CONTRIBUTORS

P.C. and J.H. developed the study concept and design, with contributions from B.S. B.S. provided the data. J.H., R.P., P.C., B.S. and F.A. established the data analysis plan. Data analysis was performed by R.P., F.A. and B.S. P.C. drafted the initial manuscript, which was revised and approved by J.H., F.A. and B.S. All authors contributed to, critically revised and approved the final version of the manuscript. All authors assume responsibility for its content. B.S. is the guarantor of this work. B.S. had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT

The datasets analysed during the current study are not publicly available as they are embedded within the framework of the Rotterdam Study.

ORCID

Petra Czarniak  https://orcid.org/0000-0001-7212-0667

REFERENCES

1. International Diabetes Federation. IDF diabetes atlas. Brussels, Belgium; 2019.  https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf
2. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9(1):6-22. doi: 10.1900/RDS.2012.9.6
3. Ahmadizar F, Ochoa-Rosales C, Glisic M, Franco OH, Muka T, Stricker BH. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol. 2019;85(5):993-1002. doi: 10.1111/bcp.13898
4. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27-37. doi: 10.5009/gnl15502
5. Malferttheiner P, Kandulska A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697-710. doi:10.1038/nrgastro.2017.117
6. Sachs G, Shin JM, Howden C. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(2):2-8. doi: 10.1111/j.1365-2036.2006.02943.x
7. Rehfell J. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol. 2011;201(4):405-411. doi: 10.1111/j.1748-1716.2010.02235.x
8. Lin H-C, Hsiao Y-T, Lin H-L, et al. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastroin-testinal disease: a population-based retrospective cohort study. Medicine. 2016;95(28):e4195. doi:10.1097/MD.0000000000004195
9. Moayyed P, Elkeelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056
10. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021;70(6):1070-1077. doi:10.1136/gutjnl-2020-322557
11. Ikram MA, Brusselle G, Ghanbari M, et al. Objectives, design and main findings until 2020 from the Rotterdam Study. Eur J Epidemiol. 2020;35(1):1-35. doi:10.1007/s10654-020-00640-5

12. Stricker BC, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol. 2010;25(4):245-251. doi:10.1007/s10654-010-9451-7

13. World Health Organisation. WHO Collaborating Centre for Drug Statistics Methodology 2019. Available from: https://www.whocc.no/atc_ddd_index/

14. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi:10.1007/BF00280883

15. Janssens J, Stolk R, Pols H, Grobbee D, Lamberts S. Serum total IGF-I, free IGF-I, and IGFBP-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998;18(2):277-282. doi:10.1161/01.ATV.18.2.277

16. De Maat M, Haverkate F, Kluit C. C-reactive protein: a cardiovascular risk factor report on the CRP hot-topic workshop October 1, 1997. Fibrinolysis Protoc. 1998;12(6):323-327. doi:10.1016/S0268-9499(98)80388-3

17. Ligthart S, van Herpt TT, Leening MJ, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(1):44-51. doi:10.1016/S2213-8587(15)00032-9

18. Koolhaas CM, Dhana K, Golubic R, et al. Physical activity types and coronary heart disease risk in middle-aged and elderly persons: the Rotterdam Study. Am J Epidemiol. 2016;183(8):729-738. doi:10.1093/aje/kww244

19. Stricker BH. Repeated interviews are much better for drug exposure assessment than a single baseline interview. Eur J Epidemiol. 2019;34(11):993-995. doi:10.1007/s10654-019-00581-8

20. Dong J-Y, Xun P, He K, Qin L-Q. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care. 2011;34(9):2116-2122. doi:10.2337/dc11-0518

21. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res. 2010;134(2):119-129. doi:10.1007/s12011-009-8465-z

22. Kieboom BC, Ligthart S, Dehghan A, et al. Serum magnesium and the risk of prediabetes: a population-based cohort study, Diabetologia. 2017;60(5):843-853. doi:10.1007/s00125-017-4224-4

23. Humphries S, Kushner H, Falkner B, Low dietary magnesium is associated with insulin resistance in a sample of young, nondiabetic Black Americans. Am J Hypertens. 1999;12(8):747-756. doi:10.1016/s0895-7061(99)00041-2

24. de Lourdes LM, Cruz T, Rodrigues LE, et al. Serum and intracellular magnesium deficiency in patients with metabolic syndrome—evidences for its relation to insulin resistance. Diabetes Res Clin Pract. 2009;83(2):257-262. doi:10.1016/j.diabres.2008.11.019

25. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993;21(6_pt_2):1024-1029. doi:10.1161/01.hyp.21.6.1024

26. Rodriguez-Morán M, Guerrero-Romero F. Insulin secretion is decreased in non-diabetic individuals with hypomagnesaeemia. Diabetes Metab Res Rev. 2011;27(6):590-596. doi:10.1002/dmrr.1206

27. Srinutta T, Chewcharat A, Takkavatakarn K, et al. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine. 2019;98(44):e17788. doi:10.1097/MD.00000000000017788

28. Novotny M, Klimova B, Valis M. PPI long term use: risk of neurological adverse events? Front Neurol. 2019;9:1142. doi:10.3389/fneur.2018.01142

29. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015;66(5):775-782. doi:10.1053/j.ajkd.2015.05.012

30. Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care. 2005;28(6):1438-1444. doi:10.2337/diacare.28.6.1438

31. Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-1 and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35(4):768-773. doi:10.2337/dc11-1833

32. Maggio M, Lauritani F, De Vita F, et al. Relationship between use of proton pump inhibitors and IGF system in older subjects. J Nutr Health Aging. 2014;18(4):420-423. doi:10.1016/j.jnha.2013.04.030

33. Wolfe MM, Soll AH. The physiology of gastric acid secretion. New Engl J Med. 1988;319(26):1707-1715. doi:10.1056/NEJM19881229319280

34. Imhann F, Bonder MJ, Vila AV, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-748. doi:10.1136/gutjnl-2015-310376

35. Martin AM, Sun EW, Rogers GB, Keating DJ. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. Front Physiol. 2019;10:428. doi:10.3389/fphys.2019.00428

36. Aw W, Fukuda S. Understanding the role of the gut ecosystem in diabetes mellitus. J Diabetes Investig. 2018;9(1):5-12. doi:10.1111/jdi.12673

37. Hukkanen J, Hakkkola J, Ryssä J. Pregnane X receptor (PXR) – a contributor to the diabetes epidemic? Drug Metabol Drug Interact. 2014;29(1-3):15. doi:10.1515/dmd-2013-0036

38. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687-702. doi:10.1210/er.2001-0038

39. Villegas K, Meier JL, Long M, Lopez J, Swislocki A. The effect of proton pump inhibitors on glycemic control in patients with type 2 diabetes. Metab Syndr Relat Disord. 2019;17(4):192-196. doi:10.1089/met.2018.0138

How to cite this article: Czarniak P, Ahmadizar F, Hughes J, et al. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol. 2022;88(6):2718-2726. doi:10.1111/bcp.15182